Home » Stocks » BTAI

BioXcel Therapeutics, Inc. (BTAI)

Stock Price: $32.51 USD -0.49 (-1.48%)
Updated May 12, 2021 4:00 PM EDT - Market closed
After-hours: $33.61 +1.10 (3.38%) May 12, 6:08 PM
Market Cap 812.84M
Revenue (ttm) n/a
Net Income (ttm) -93.63M
Shares Out 24.52M
EPS (ttm) -3.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 12
Last Price $32.51
Previous Close $33.00
Change ($) -0.49
Change (%) -1.48%
Day's Open 32.53
Day's Range 32.31 - 33.86
Day's Volume 419,853
52-Week Range 28.00 - 71.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Granted FDA Breakthrough Therapy designation for BXCL501 for the acute treatment of agitation associated with dementia; registrational program expected to begin in 2H 2021

2 days ago - GlobeNewsWire

NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence ap...

1 week ago - GlobeNewsWire

NEW HAVEN, Conn., May 03, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence ap...

1 week ago - GlobeNewsWire

NEW HAVEN, Conn., April 26, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence ...

2 weeks ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - April 16, 2021) - Levi & Korsinsky announces it has commenced an investigation of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) concerning possible breaches of fiduciar...

3 weeks ago - Newsfile Corp

Investors were not impressed with the biotech's latest clinical update.

1 month ago - The Motley Fool

BioXcel Therapeutics Inc (NASDAQ: BTAI) has announced topline results from its Phase 1b/2 proof-of-concept RELEASE study evaluating BXCL501 for the treatment of opioid withdrawal symptoms. BXCL501 is th...

1 month ago - Benzinga

Primary safety endpoint achieved in first study of BXCL501 dosed twice-daily over seven days

1 month ago - GlobeNewsWire

The FDA has designated Breakthrough Therapy status to BioXcel Therapeutics Inc's (NASDAQ: BTAI) BXCL501, to treat agitation associated with dementia. The designation intends to expedite the development ...

1 month ago - Benzinga

Designation offers the potential for expedited development and review, highlighting the urgent need for new treatment options for dementia related agitation Designation offers the potential for expedite...

1 month ago - GlobeNewsWire

New Drug Application (“NDA”) submitted to the U.S. Food and Drug Administration (“FDA”) for BXCL501 for the acute treatment of schizophrenia and bipolar disorder related agitation

2 months ago - GlobeNewsWire

NEW HAVEN, Conn., March 04, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence ...

2 months ago - GlobeNewsWire

BioXcel Therapeutics Inc (NASDAQ: BTAI) plans to finalize study design, dosing, and endpoints for its BXCL501 Phase 3 program in dementia-related agitation. The end of the Phase 2 meeting with the FDA i...

2 months ago - Benzinga

Review of TRANQUILITY data show ed 30 mcg dose met statistical significance across multiple scales

2 months ago - GlobeNewsWire

Former Allergan executive brings extensive global regulatory experience across multiple therapeutic areas Former Allergan executive brings extensive global regulatory experience across multiple therapeu...

2 months ago - GlobeNewsWire

BioXcel Therapeutics Inc (NASDAQ: BTAI) initiated the Phase 2 PLACIDITY trial evaluating BXCL501 to treat delirium-related agitation. The 20 subject-trial is designed to evaluate the safety, efficacy, a...

2 months ago - Benzinga

NEW HAVEN, Conn., Feb. 23, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence a...

2 months ago - GlobeNewsWire

Live webcast to be held on February 19th from 11:00 am ET to 2:00 pm ET Live webcast to be held on February 19th from 11:00 am ET to 2:00 pm ET

3 months ago - GlobeNewsWire

NEW HAVEN, Conn., Feb. 04, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence a...

3 months ago - GlobeNewsWire

A Wall Street analyst has high hopes for the company.

3 months ago - The Motley Fool

High-growth names with positive catalysts that can outperform the markets make these some of the best investments to start 2021. The post 4 of the Best Investments to Start 2021 appeared first on Invest...

Other stocks mentioned: RADA, TDOC, XPEV
3 months ago - InvestorPlace

BioXcel uses a proprietary AI program to screen for ways to repurpose old drugs and screen for useful biomarkers that can allow for faster, safer, and cheaper drug development. BioXcel's lead asset BXCL...

4 months ago - Seeking Alpha

Company to present corporate update and plans for 2021

4 months ago - GlobeNewsWire

Grant will support clinical studies in patients with post-traumatic stress disorder related to alcohol and substance abuse Grant will support clinical studies in patients with post-traumatic stress diso...

5 months ago - GlobeNewsWire

NEW HAVEN, Conn., Nov. 13, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to id...

5 months ago - GlobeNewsWire

BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Complete NDA submission for BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorders on track for Q1 2021

6 months ago - GlobeNewsWire

Initiated rolling submission of New Drug Application (“NDA”) with U.S. Food and Drug Administration (“FDA”)

6 months ago - GlobeNewsWire

Encouraging signals of activity in difficult-to-treat tumors observed in both ongoing trials with BXCL701 and pembrolizumab (KEYTRUDA®)

6 months ago - GlobeNewsWire

NEW HAVEN, Conn., Nov. 05, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identi...

6 months ago - GlobeNewsWire

Fifth potential indication for BXCL501, an orally dissolving thin film Fifth potential indication for BXCL501, an orally dissolving thin film

6 months ago - GlobeNewsWire

BioXcel product candidates use the 505(b)(2) approval pathway. Successful pivotal trials for two indications in acute agitation.

6 months ago - Seeking Alpha

Today, we look at a promising CNS play called BioXcel Therapeutics. The shares have lost more than a third from their pre-secondary offering highs.

7 months ago - Seeking Alpha

With the third quarter of what has proven to be a remarkable 2020 coming to a close, many of the firms we cover across Wall Street already are looking to the stretch run of the year and at what should b...

Other stocks mentioned: CI, HAE, HZNP, VRTX
7 months ago - 24/7 Wall Street

In 2020, the central nervous system (CNS) market has largely failed to keep up with $IBB.

7 months ago - Seeking Alpha

NEW HAVEN, Conn., Sept. 09, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to ide...

8 months ago - GlobeNewsWire

BioXcel Therapeutics' (BTAI) CEO Vimal Mehta on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Investors were not impressed with the company's latest quarterly update.

8 months ago - The Motley Fool

SERENITY I & II Phase 3 trials of BXCL501 achieved all primary and secondary endpoints; New Drug Application (“NDA”) submission to U.S. Food and Drug Administration (“FDA”) planned for Q1 2021

8 months ago - GlobeNewsWire

NEW HAVEN, Conn., Aug. 07, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to iden...

9 months ago - GlobeNewsWire

NEW HAVEN, Conn., July 28, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced the pric...

9 months ago - GlobeNewsWire

NEW HAVEN, Conn., July 27, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced that it ...

9 months ago - GlobeNewsWire

The company reported positive results from two pivotal clinical trials.

9 months ago - The Motley Fool

Bioxcel Therapeutics unveiled bullish Phase 3 results for an agitation treatment in patients with schizophrenia and bipolar disorder Monday — pushing BTAI stock to a record high. The post Bioxcel Therap...

9 months ago - Investors Business Daily

Highly statistically significant improvements in PEC score observed vs. placebo (p

9 months ago - GlobeNewsWire

Company providing BXCL501 to evaluate its activity in patients with COVID-19 that may require calming or arousable sedation following intubation Company providing BXCL501 to evaluate its activity in pat...

10 months ago - GlobeNewsWire

Patent is expected to extend IP protection until 2039 Patent is expected to extend IP protection until 2039

10 months ago - GlobeNewsWire

Will lead global clinical development strategy and medical affairs for the Company’s neuroscience programs Will lead global clinical development strategy and medical affairs for the Company’s neuroscien...

10 months ago - GlobeNewsWire

Here's why investors shouldn't bet on these two companies long-term, at least not yet.

Other stocks mentioned: CRON
10 months ago - The Motley Fool

Former Allergan Commercial Head to lead commercialization efforts for BXCL501 across multiple neuropsychiatric disorders Former Allergan Commercial Head to lead commercialization efforts for BXCL501 acr...

10 months ago - GlobeNewsWire

About BTAI

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. h... [Read more...]

Industry
Biotechnology
IPO Date
Mar 8, 2018
CEO
Vimal Mehta
Employees
50
Stock Exchange
NASDAQ
Ticker Symbol
BTAI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for BTAI stock is "Strong Buy." The 12-month stock price forecast is 102.00, which is an increase of 213.75% from the latest price.

Price Target
$102.00
(213.75% upside)
Analyst Consensus: Strong Buy